GLP-1 Drug Pipeline Tracker
Search 79 weight loss drugs in the GLP-1 pipeline, from first human trials to pharmacy shelves, by class, company, route and sourced status.
Jump to closest to approval, available today or FAQs
Search the pipeline
Data as of November 18, 2026
- 13 Approved
- 10 Submitted
- 19 Phase 3
- 18 Phase 2
- 7 Phase 1
- 12 Discontinued
79 drugs shown
Discontinued drugs are left out here.
No drugs match. Clear the search or turn off a filter.
| Class | Drug | Company | Status | Route | Latest status note |
|---|---|---|---|---|---|
| GLP-1 RA 21 drugs | |||||
| GLP-1 RA | Albiglutide Tanzeum | GSK | Discontinued | Injection, weekly | Tanzeum is listed as discontinued in the FDA's Drugs@FDA database; its last label supplement dates from December 2017. Source for Albiglutide |
| GLP-1 RA | Beinaglutide | Shanghai Benemae | Approved | Injection | China's NMPA approved beinaglutide for adult weight management in July 2023. Source for Beinaglutide |
| GLP-1 RA | Berobenatide PF-08653944; MET-097i | Pfizer | Phase 3 | Injection, weekly or monthly | Pfizer's November 2026 pipeline lists it in Phase 3; the first Phase 3 trial (VESPER-4) began in December 2025. Source for Berobenatide |
| GLP-1 RA | Bofanglutide GZR18 | Gan & Lee Pharmaceuticals | Submitted | Injection, every two weeks | China's NMPA accepted a marketing application for long-term weight management in September 2026. Source for Bofanglutide |
| GLP-1 RA | Dulaglutide Trulicity | Eli Lilly | Approved | Injection, weekly | Approved by the FDA in September 2014 for type 2 diabetes as Trulicity; it is not approved for weight loss. Source for Dulaglutide |
| GLP-1 RA | Ecnoglutide XW003 | Sciwind Biosciences | Approved | Injection, weekly | China's NMPA approved the weekly injection for chronic weight management in March 2026. Source for Ecnoglutide |
| GLP-1 RA | Efpeglenatide | Hanmi Pharmaceutical | Approved | Injection, weekly | South Korea's MFDS approved it for chronic weight management in adults without diabetes in October 2026. Source for Efpeglenatide |
| GLP-1 RA | Efsubaglutide alfa supaglutide | Innogen | Approved | Injection, weekly | Approved in China for type 2 diabetes in January 2025; an obesity Phase 3 finished its main follow-up in July 2026. Source for Efsubaglutide alfa |
| GLP-1 RA | Exenatide Byetta; Bydureon | AstraZeneca | Discontinued | Injection, twice daily or weekly | Byetta and Bydureon are listed as discontinued in the FDA's Drugs@FDA database; their last supplements date from 2025. Source for Exenatide |
| GLP-1 RA | HDM1702 semaglutide injection (Huadong) | Huadong Medicine | Submitted | Injection, weekly | China's NMPA accepted Huadong's application for its semaglutide injection in weight management in April 2026. Source for HDM1702 |
| GLP-1 RA | Liraglutide Victoza; Saxenda | Novo Nordisk | Approved | Injection, daily | Approved by the FDA for weight management as Saxenda in December 2014, after a 2010 diabetes approval as Victoza. Source for Liraglutide |
| GLP-1 RA | Lixisenatide Adlyxin; Lyxumia | Sanofi | Discontinued | Injection, daily | The EU authorization for Lyxumia was withdrawn in December 2025; the drug remains in the insulin combination Soliqua. Source for Lixisenatide |
| GLP-1 RA | Loxenatide PEG-loxenatide; PEX168 | Jiangsu Hansoh | Approved | Injection, weekly | Approved in China for type 2 diabetes in May 2019; it is not approved for weight management. Source for Loxenatide |
| GLP-1 RA | MET-224o PF-08656796 | Pfizer | Discontinued | Oral | Pfizer removed this oral peptide from its pipeline in August 2026 while it was in Phase 1. Source for MET-224o |
| GLP-1 RA | Noiiglutide SHR20004 | Jiangsu Hengrui | Phase 2 | Injection | An obesity Phase 2 trial began in March 2021 with no registry update since 2022; a diabetes Phase 3 trial is complete. Source for Noiiglutide |
| GLP-1 RA | Semaglutide Ozempic; Wegovy | Novo Nordisk | Approved | Injection, weekly | Approved by the FDA for weight management as Wegovy in June 2021, after a 2017 diabetes approval as Ozempic. Source for Semaglutide |
| GLP-1 RA | Semaglutide oral Rybelsus; Wegovy tablets | Novo Nordisk | Approved | Oral, daily | The FDA approved Wegovy tablets for weight management in December 2025; the diabetes tablet dates from 2019. Source for Semaglutide oral |
| GLP-1 RA | Taspoglutide | Roche | Discontinued | Injection, weekly | Roche stopped development and returned the drug to Ipsen in February 2011 after tolerability problems in Phase 3. Source for Taspoglutide |
| GLP-1 RA | TG103 efmedaglutide alfa | CSPC Pharmaceutical | Submitted | Injection, weekly | China's NMPA accepted a marketing application for long-term weight management in October 2025. Source for TG103 |
| GLP-1 RA | Visepegenatide PB-119 | PegBio | Approved | Injection | China's NMPA approved it for type 2 diabetes in November 2025; its obesity program is at Phase 1b/2a. Source for Visepegenatide |
| GLP-1 RA | VRB-101 oral ecnoglutide | Verdiva Bio | Phase 2 | Oral, weekly | One Phase 2 trial of weekly oral ecnoglutide is complete; a second was ended in October 2026 for business reasons. Source for VRB-101 |
| GLP-1/GIP 11 drugs | |||||
| GLP-1/GIP | BGM0504 | BrightGene | Submitted | Injection, weekly | China's NMPA accepted a marketing application for long-term weight management in June 2026. Source for BGM0504 |
| GLP-1/GIP | Brenipatide LY3537031 | Eli Lilly | Phase 1 | Injection | Obesity work is at Phase 1; Lilly's Phase 3 trials, begun in October 2025, are in alcohol use disorder and depression. Source for Brenipatide |
| GLP-1/GIP | Enicepatide CT-388; RO7795068 | Roche | Phase 3 | Injection | Roche's Phase 3 obesity trials began in March 2026. Source for Enicepatide |
| GLP-1/GIP | HDM1005 poterepatide | Huadong Medicine | Phase 3 | Injection, weekly | A Phase 3 obesity trial in China began in October 2025; enrollment was complete by Huadong's September 2026 report. Source for HDM1005 |
| GLP-1/GIP | NNC0519-0130 | Novo Nordisk | Phase 2 | Injection, weekly | Its obesity Phase 2 trial ended its main phase in April 2025; Novo's Q3 2026 pipeline overview does not show it. Source for NNC0519-0130 |
| GLP-1/GIP | Olatorepatide HS-20094 | Hansoh Pharma; Regeneron | Submitted | Injection, weekly | China's NMPA accepted a weight-management application in June 2026; Regeneron holds rights outside Greater China. Source for Olatorepatide |
| GLP-1/GIP | RAY1225 bilpatide | Guangdong Zhongsheng Pharmaceutical | Phase 3 | Injection, every two weeks | A Phase 3 obesity trial in China met its main goal in October 2026; no marketing application had been announced. Source for RAY1225 |
| GLP-1/GIP | Ribupatide HRS9531; KAI-9531 | Jiangsu Hengrui; Kailera | Submitted | Injection, weekly | China's NMPA accepted a weight-management application in September 2025; Kailera runs global Phase 3 trials. Source for Ribupatide |
| GLP-1/GIP | Tirzepatide Mounjaro; Zepbound | Eli Lilly | Approved | Injection, weekly | Approved by the FDA for weight management as Zepbound in November 2023, after a 2022 diabetes approval as Mounjaro. Source for Tirzepatide |
| GLP-1/GIP | VK2735 | Viking Therapeutics | Phase 3 | Injection | Phase 3 trials of the injection (VANQUISH) began in June 2025 and were still running in November 2026. Source for VK2735 |
| GLP-1/GIP | VK2735 oral | Viking Therapeutics | Phase 3 | Oral | Two Phase 3 trials of the tablet (SUNRISE) were listed as recruiting in November 2026. Source for VK2735 oral |
| GLP-1/glucagon 6 drugs | |||||
| GLP-1/glucagon | Cotadutide MEDI0382 | AstraZeneca | Discontinued | Injection, daily | AstraZeneca dropped the daily injection in April 2023 to focus on a once-weekly successor. Source for Cotadutide |
| GLP-1/glucagon | DA-1726 | MetaVia; Dong-A ST | Phase 1 | Injection, weekly | MetaVia's November 2026 update keeps it in Phase 1, with a Phase 2 liver-disease study planned for late 2027. Source for DA-1726 |
| GLP-1/glucagon | Efinopegdutide MK-6024 | Merck & Co. | Phase 2 | Injection, weekly | Merck's November 2026 pipeline lists it in Phase 2 for the liver disease MASH; it has no active obesity trial. Source for Efinopegdutide |
| GLP-1/glucagon | Mazdutide IBI362 | Innovent Biologics | Approved | Injection, weekly | China's NMPA approved it for chronic weight management in June 2025. Source for Mazdutide |
| GLP-1/glucagon | Pemvidutide ALT-801 | Altimmune | Phase 2 | Injection, weekly | Its obesity Phase 2 trial ended in 2023; a Phase 3 trial in the liver disease MASH began in July 2026. Source for Pemvidutide |
| GLP-1/glucagon | Survodutide BI 456906 | Boehringer Ingelheim | Phase 3 | Injection, weekly | Phase 3 heart-safety results were reported in November 2026; Boehringer Ingelheim plans regulatory filings in 2027. Source for Survodutide |
| GIP/GLP-1/glucagon 4 drugs | |||||
| GIP/GLP-1/glucagon | Efocipegtrutide HM15211 | Hanmi Pharmaceutical | Phase 2 | Injection, weekly | A Phase 2 trial in the liver disease MASH finished in July 2026; it has no obesity trial beyond Phase 1. Source for Efocipegtrutide |
| GIP/GLP-1/glucagon | MWN101 | Shanghai Minwei Biotechnology | Phase 2 | Injection | Its obesity Phase 2 trial in China ended in November 2024; a sister compound, MWN109, entered Phase 3 in 2026. Source for MWN101 |
| GIP/GLP-1/glucagon | Retatrutide LY3437943 | Eli Lilly | Phase 3 | Injection, weekly | Lilly reported further Phase 3 results in October 2026 and plans to file with the FDA in the first quarter of 2027. Source for Retatrutide |
| GIP/GLP-1/glucagon | UBT251 | United Laboratories; Novo Nordisk | Phase 3 | Injection | A Phase 3 obesity trial in China began in September 2026; Novo Nordisk expects global Phase 1/2 results in 2027. Source for UBT251 |
| Amylin & combos 10 drugs | |||||
| Amylin & combos | ACCG-2671 | Structure Therapeutics | Phase 1 | Oral | The multiple-dose part of a Phase 1/2a trial was under way in November 2026, with results due in early 2027. Source for ACCG-2671 |
| Amylin & combos | Cagrilintide | Novo Nordisk | Phase 3 | Injection, weekly | Phase 3 trials of cagrilintide on its own (RENEW) began in November 2025, with results expected in mid-2027. Source for Cagrilintide |
| Amylin & combos | CagriSema cagrilintide + semaglutide | Novo Nordisk | Submitted | Injection, weekly | Novo Nordisk filed with the FDA in December 2025; no decision had been announced by mid-November 2026. Source for CagriSema |
| Amylin & combos | Eloralintide LY3841136 | Eli Lilly | Phase 3 | Injection | Phase 3 trials began in December 2025; Lilly's October 2026 pipeline lists it in Phase 3 for obesity. Source for Eloralintide |
| Amylin & combos | EloraTZP LY900043; eloralintide + tirzepatide | Eli Lilly | Phase 3 | Injection | A Phase 3 trial of eloralintide combined with tirzepatide began in October 2026. Source for EloraTZP |
| Amylin & combos | MET-233i PF-08653945 | Pfizer | Phase 2 | Injection, weekly or monthly | Pfizer began a Phase 2b trial (SOLIS-1), alone and with berobenatide, in May 2026; results are expected in 2027. Source for MET-233i |
| Amylin & combos | Petrelintide ZP8396; RO7895515 | Zealand Pharma; Roche | Phase 3 | Injection, weekly | Roche and Zealand Pharma began Phase 3 obesity trials in September 2026. Source for Petrelintide |
| Amylin & combos | Pramlintide Symlin | AstraZeneca | Discontinued | Injection, at mealtimes | The FDA listed Symlin, a 2005 diabetes drug, as being discontinued by AstraZeneca in October 2025. Source for Pramlintide |
| Amylin & combos | VRB-103 | Verdiva Bio | Phase 1 | Oral | A Phase 1 trial, alone and with oral ecnoglutide, began in July 2026. Source for VRB-103 |
| Amylin & combos | Zenagamtide amycretin; NNC0487-0111 | Novo Nordisk | Phase 3 | Injection | Phase 3 obesity trials (AMAZE) began in February 2026; a Phase 3 trial of the oral form began in September 2026. Source for Zenagamtide |
| Oral small molecule 17 drugs | |||||
| Oral small molecule | Aleniglipron GSBR-1290 | Structure Therapeutics | Phase 3 | Oral | Two Phase 3 trials (ACCOMPLISH) started in summer 2026 (company: August), with results expected in late 2028. Source for Aleniglipron |
| Oral small molecule | ASC30 oral | Ascletis | Phase 3 | Oral, daily | Two Phase 3 trials of the once-daily tablet (AURORA) began in August 2026. Source for ASC30 oral |
| Oral small molecule | Danuglipron PF-06882961 | Pfizer | Discontinued | Oral | Pfizer ended development in April 2025 after a possible drug-related liver injury in one trial participant. Source for Danuglipron |
| Oral small molecule | Elecoglipron AZD5004; ECC5004 | AstraZeneca | Phase 3 | Oral | AstraZeneca's Phase 3 weight-management trials began in June 2026. Source for Elecoglipron |
| Oral small molecule | HDM1002 conveglipron | Huadong Medicine | Submitted | Oral, daily | China's NMPA accepted a marketing application for long-term weight control in November 2026. Source for HDM1002 |
| Oral small molecule | Lotiglipron PF-07081532 | Pfizer | Discontinued | Oral | Pfizer ended development in June 2023 after raised liver enzymes were seen in trials. Source for Lotiglipron |
| Oral small molecule | LY4086940 | Eli Lilly | Phase 1 | Oral | Phase 1 is complete; a Phase 2 obesity trial was registered but had not begun recruiting as of November 2026. Source for LY4086940 |
| Oral small molecule | MDR-001 | MindRank | Phase 3 | Oral | The first participant in a Phase 3 obesity trial in China was dosed in February 2026. Source for MDR-001 |
| Oral small molecule | Naperiglipron LY3549492 | Eli Lilly | Phase 2 | Oral | Lilly's October 2026 pipeline lists it in Phase 2; its main obesity trial finished in May 2026. Source for Naperiglipron |
| Oral small molecule | Orforglipron Foundayo; LY3502970 | Eli Lilly | Approved | Oral, daily | The FDA approved it for weight management as Foundayo in April 2026. Source for Orforglipron |
| Oral small molecule | RGT-075 RGT001-075 | Regor Pharmaceuticals | Phase 2 | Oral, daily | Its most recent Phase 2 obesity trial is complete; the registry record was last updated in May 2026. Source for RGT-075 |
| Oral small molecule | Safiglipron HRS-7535; KAI-7535 | Jiangsu Hengrui; Kailera | Submitted | Oral, daily | China's NMPA accepted a weight-management application in September 2026; Kailera runs a global Phase 2 trial. Source for Safiglipron |
| Oral small molecule | SAL0150 | Shenzhen Salubris | Phase 1 | Oral, weekly | A first-in-human study that includes people with obesity was registered in March 2026. Source for SAL0150 |
| Oral small molecule | TERN-601 | Terns Pharmaceuticals (Merck) | Discontinued | Oral, daily | Terns ended development in October 2025 after Phase 2 results; Merck acquired Terns in May 2026. Source for TERN-601 |
| Oral small molecule | Tifeglipron CT-996; RO7795081 | Roche | Phase 2 | Oral, daily | A Phase 2 obesity trial finished its main phase in April 2026; no Phase 3 trial is registered. Source for Tifeglipron |
| Oral small molecule | TQF3250 | Sino Biopharm (Chia Tai Tianqing) | Phase 1 | Oral | A Phase 1 trial in people with overweight or obesity began in September 2026. Source for TQF3250 |
| Oral small molecule | VCT220 CX11 | Vincentage Pharma; Corxel | Submitted | Oral, daily | A marketing application in China was reported as accepted in July 2026 after a positive Phase 3 obesity trial. Source for VCT220 |
| Other 10 drugs | |||||
| Other | ABBV-295 GUB014295 | AbbVie | Phase 2 | Injection | AbbVie began a Phase 2 trial in adults with obesity or overweight in August 2026. Source for ABBV-295 |
| Other | Acmopatide CT-868; RO7795074 | Roche | Phase 2 | Injection | A Phase 2 trial in adults with type 1 diabetes and overweight or obesity is complete; record updated October 2026. Source for Acmopatide |
| Other | Apitegromab | Scholar Rock | Phase 2 | Injection | A Phase 2 trial in adults with overweight or obesity is complete; the registry record was updated in January 2026. Source for Apitegromab |
| Other | Bimagrumab LY3985863 | Eli Lilly | Phase 2 | Injection | Lilly's October 2026 pipeline lists it in Phase 2 for obesity. Source for Bimagrumab |
| Other | Dapiglutide ZP7570 | Zealand Pharma | Discontinued | Injection, weekly | Zealand Pharma paused this GLP-1/GLP-2 drug after Phase 1b in November 2025 and still lists it as paused. Source for Dapiglutide |
| Other | Enobosarm | Veru | Phase 2 | Oral | A further Phase 2 trial in people with obesity or overweight began in March 2026. Source for Enobosarm |
| Other | Garetosmab | Regeneron | Phase 2 | Injection | A Phase 2 trial with trevogrumab and semaglutide is complete; the registry record was updated in November 2026. Source for Garetosmab |
| Other | Maridebart cafraglutide MariTide; AMG 133 | Amgen | Phase 3 | Injection | Amgen's Phase 3 obesity trials began in March 2025; further Phase 3 trials opened in October 2026. Source for Maridebart cafraglutide |
| Other | PF-07976016 | Pfizer | Discontinued | Oral | Pfizer ended development of this GIP receptor blocker in August 2026 after reviewing Phase 2a data. Source for PF-07976016 |
| Other | Trevogrumab | Regeneron | Phase 2 | Injection | A Phase 2 trial with semaglutide, with or without garetosmab, is complete; record updated November 2026. Source for Trevogrumab |
Submitted means a regulator is reviewing the marketing application (elsewhere called Filed). Approved means approved in at least one country, not always by the FDA. Drug names open ClinicalTrials.gov in a new tab.
How to read the GLP-1 pipeline tracker
The tracker covers 79 drugs: GLP-1 medications, drugs that pair GLP-1 with other hormone targets, and a few others in trials for weight loss. List shows each drug with its class, company, status, route and a sourced note. By stage puts the same drugs in a grid from the earliest stage to Approved, minus discontinued ones.
What Phase 1, 2, 3, Submitted and Approved mean
A status is the furthest stage a drug has reached for obesity or weight management. Phase definitions are the FDA’s.1
| Status | What it means |
|---|---|
| Phase 1 | 20 to 100 volunteers over several months, to check safety and dosage. |
| Phase 2 | Up to several hundred people with the condition, to study efficacy and side effects. About 33% move on. |
| Phase 3 | 300 to 3,000 people over 1 to 4 years, to confirm benefit and monitor adverse reactions. About 25% to 30% move on. |
| Submitted | A regulator has accepted the company’s marketing application and is reviewing it. Elsewhere called Filed. |
| Approved | Approved in at least one country. The note says where, and for what. |
| Discontinued | Development stopped or paused, or the product was withdrawn. |
GLP-1 drug classes in the tracker
Drugs are grouped by the receptors they target.
- GLP-1 RA (21 drugs). Agonists of the GLP-1 receptor only, such as semaglutide (Ozempic®, Wegovy®).
- GLP-1/GIP (11). Two receptors. Tirzepatide (Mounjaro®, Zepbound®) is approved.2
- GLP-1/glucagon (6). Survodutide and mazdutide.
- GIP/GLP-1/glucagon (4). Triple agonists such as retatrutide.
- Amylin and combinations (10). Cagrilintide, alone or paired with semaglutide as CagriSema.
- Oral small molecule (17). Non-peptide pills. Orforglipron (Foundayo®) is the only approved one.3
- Other (10). Other targets, including the antibody bimagrumab.
Which new weight loss drugs are closest to approval?
CagriSema is closest in the United States. Novo Nordisk filed it with the FDA in December 2025, and no decision had been announced by November 18, 2026.4
Retatrutide and survodutide are in Phase 3. Eli Lilly plans to submit retatrutide to the FDA in the first quarter of 2027, and Boehringer Ingelheim plans to file survodutide in 2027.5,6
The other Submitted drugs are under review in China, most recently Huadong Medicine’s daily pill HDM1002 (accepted November 2, 2026).7
Recent changes
- December 22, 2025: FDA approval of Wegovy tablets, a daily semaglutide pill.8
- April 1, 2026: FDA approval of orforglipron (Foundayo), a daily pill.3
- October 7, 2026: South Korea approved efpeglenatide for weight management.9
How the data is checked, and its limits
Every row was re-checked on November 18, 2026 against a company document, a regulator, ClinicalTrials.gov or a journal, and links to its source. For 14 of the 79 drugs, part of the entry rests on trade press or could not be confirmed.
- Statuses are for obesity. Pemvidutide is in Phase 3 for a liver disease but Phase 2 here.
- Approved can mean approved abroad, or for diabetes rather than weight loss. The note says which.
- Recent decisions can be missing, especially for applications in China.
What you can get through Zealthy today
Drugs still in trials are not available from Zealthy, or from anyone else outside a clinical trial. The FDA says retatrutide and cagrilintide cannot be used in compounding.10
A licensed Zealthy provider can prescribe these when appropriate for you:
- Wegovy and Zepbound, FDA-approved for weight management.11,12
- Ozempic and Mounjaro, FDA-approved for type 2 diabetes. Weight loss is an off-label use.2,13
- Compounded semaglutide and compounded tirzepatide. Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality.10
When your plan covers a brand-name medication, the copay can be as low as $25 a month with an active Zealthy membership. See also the supply tracker and insurance coverage checker.
GLP-1 pipeline FAQs
When will retatrutide be approved?
No approval date has been set. Retatrutide is in Phase 3, and Eli Lilly plans to submit it to the FDA in the first quarter of 2027.5 A submission starts a review and does not guarantee approval. Until then, it is available only inside a clinical trial.
Is there a GLP-1 pill for weight loss?
Yes. Two daily pills are FDA-approved for weight management: Wegovy tablets (oral semaglutide), approved December 22, 2025, and Foundayo (orforglipron), approved April 1, 2026.3,8 The tracker lists 25 oral drugs. Most are still in trials, and 5 have been discontinued.
Does Approved in the tracker mean FDA-approved?
Not always. Approved means a regulator in at least one country has approved the drug. Of the 13 Approved drugs, 6 are FDA-approved and 7 are approved only in China or South Korea. Four are for type 2 diabetes, not weight loss.
Can Zealthy prescribe retatrutide or other drugs in clinical trials?
No. Drugs still in trials are not available from Zealthy, or from anyone else outside a clinical trial. Zealthy providers prescribe Wegovy, Zepbound, Ozempic, Mounjaro, and compounded semaglutide or tirzepatide when a licensed provider finds one appropriate. Compounded medications are not FDA-approved.
What is the difference between Phase 3 and Submitted?
Phase 3 means the drug is still being tested in large trials, usually 300 to 3,000 people over 1 to 4 years.1 Submitted means a regulator has accepted the company’s application and is reviewing it. Acceptance for review is not approval.
Important safety information
Boxed warning: semaglutide and tirzepatide cause thyroid C-cell tumors in rodents; whether they do in people is unknown. Do not use them with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).11,12
Do not use them after a serious allergic reaction to the drug. Serious risks include pancreatitis, gallbladder problems, low blood sugar, kidney injury and severe stomach problems. Common side effects are nausea, diarrhea, vomiting and constipation.11,12
Full safety information: Wegovy, Zepbound, Ozempic, Mounjaro, semaglutide, tirzepatide.
Sources
- FDA. Step 3: Clinical Research. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
- Mounjaro prescribing information. Eli Lilly. https://pi.lilly.com/us/mounjaro-uspi.pdf
- FDA. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- Novo Nordisk. CagriSema press release, ObesityWeek 2026. https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine-9-trial-obesityweek-2026.html
- Eli Lilly. Retatrutide Phase 3 press release, October 28, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- Boehringer Ingelheim. Survodutide press release, November 9, 2026. https://www.globenewswire.com/fr/news-release/2026/11/09/3398586/0/en/boehringer-ingelheim-s-survodutide-is-the-first-glucagon-glp-1-dual-agonist-to-demonstrate-a-favorable-cardiovascular-safety-profile-in-global-phase-iii-synchronize-cvot-trial-alon.html
- Huadong Medicine. HDM1002 application notice. https://en.huadongmedicine.com/companynews/414/
- FDA. Drugs@FDA: NDA 218316, Wegovy tablets. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
- Hanmi Pharmaceutical. Efpeglenatide approval press release. https://www.hanmi.co.kr/about/news-media/press/detail-5083.hm
- FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Wegovy prescribing information. Novo Nordisk. https://www.novo-pi.com/wegovy.pdf
- Zepbound prescribing information. Eli Lilly. https://pi.lilly.com/us/zepbound-uspi.pdf
- Ozempic prescribing information. Novo Nordisk. https://www.novo-pi.com/ozempic.pdf
Start with a GLP-1 that is available today
Answer a few health questions online. A licensed provider reviews them, and membership starts at $39 for the first month.

A provider works with what is approved now
A U.S.-licensed physician or nurse practitioner reviews your health history and tells you which available medication, if any, is appropriate.
The medical information on this page is reviewed by the Zealthy care team against FDA prescribing information and published clinical trials. It is general education, not personal medical advice.
What Zealthy members say
One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
I started semaglutide at the recommendation of my Zealthy provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and Zealthy was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Since I started, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Individual results may vary. These are the experiences of Zealthy members and are not a guarantee of any outcome. Medication is prescribed only when a licensed provider finds it appropriate.
GLP-1 medications Zealthy providers can prescribe
Brand-name or compounded, a licensed provider decides what fits your health history. Our insurance team handles the prior authorization paperwork for brand-name medication.
Zepbound®
Tirzepatide, FDA-approved for weight management and for sleep apnea in adults with obesity.
Zepbound cost, savings card and side effects →Wegovy®
Semaglutide, FDA-approved for weight management, as a weekly injection or a daily pill.
Wegovy pill, cost and side effects →Mounjaro®
Tirzepatide, FDA-approved for type 2 diabetes. The same ingredient as Zepbound.
Mounjaro doses and savings card →Ozempic®
Semaglutide, FDA-approved for type 2 diabetes. Weight loss is an off-label use.
Ozempic side effects and cost →Compounded semaglutide
$199 a month, or from $106 a month on a 3-month supply, shipping included. Not FDA-approved.
Semaglutide cost and dosing →Compounded tirzepatide
$329 a month, or from $216 a month on a 3-month supply, shipping included. Not FDA-approved.
Tirzepatide dosage and cost →Compounded medications are prepared by a partner pharmacy for an individual prescription. They are not FDA-approved, which means the FDA has not reviewed them for safety, effectiveness or quality. Zealthy membership ($39 for the first month, then $135 a month) is billed separately from medication. A prescription is written only if a licensed provider finds it appropriate.